Reviewer’s report

Title: Prevalence and Spectrum of MLH1, MSH2, and MSH6 Pathogenic Germline Variants in Pakistani Colorectal Cancer Patients

Version: 1 Date: 01 Jul 2019

Reviewer: Andrzej Plawski

Reviewer's report:

Dear colleague

You stated in highlighted text "The majority of CRC and EC are not linked with inherited cancer syndromes, but up to 30% of CRC are hereditary and these are generally divided into polyposis and non-polyposis syndromes." and cited [2] the Dominguez-Valentin M, Therkildsen C, Da Silva S, Nilbert M. Familial colorectal cancer type X: genetic profiles and phenotypic features. Mod Pathol. 2015;28:30-6. But the Dominquez at al had stated in in fist lines of their publication "Heredity represents a major cause of colorectal cancer, with at least 20% of the cases estimated to develop because of genetic factors (https://www.nature.com/articles/modpathol201449.pdf).


Wood et al had stated "Colorectal cancer (CRC) is the second most frequent cancer in developed countries. Inherited susceptibility is responsible for ~35% of all cases"

It had better if you clarify it.

I am not native but the sentence

"The most common pathogenic MMR gene variants in LS are reported in MLH1 and MSH2 (up to 90%)" is not the best of all I have ever seen. I think you want to say that most (up to 90%) mutations causing LS are reported in MLH1 and MSH2 genes. I have no suggestion but you can consider improving this sentence.

Level of interest
Please indicate how interesting you found the manuscript:

An article of importance in its field

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below.

If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal